All In Biotech

Drug Trial Radar · NCT07512427

Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of OPK-88006 in Healthy and Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) Participants

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 24, 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
OPKO Health, Inc.Industry
Sponsor type
Industry
First posted
Apr 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Two-part Phase 1/2 study of OPK-88006, including an open-label SAD phase in healthy participants and a double-blind, randomized, placebo-controlled MAD phase in participants with presumed MASH, to evaluate safety, PK, and MASH related pharmacodynamic changes compared to placebo.

Conditions

  • MASH

Interventions

  • OPK-88006Drug

    Administered by subcutaneous injection

  • PlaceboDrug

    Administered by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAD - OPK-88006 maximum plasma concentration (Cmax)Time frame: 2 hours to 1 week
  2. SAD - OPK-88006 Time to peak (Tmax)Time frame: 2 hours to 1 week
  3. SAD - OPK-88006 Elimination half-life (T1/2)Time frame: 10 hours to 200 hours
  4. SAD - Frequency of treatment emergent adverse events (TEAE)Time frame: Up to 2 weeks
  5. MAD - Frequency of treatment emergent adverse events (TEAE)Time frame: Up to 20 weeks
  6. MAD - Change in body weightTime frame: Up to 17 weeks
  7. MAD - Change in fasting lipidsTime frame: Up to 17 weeks
  8. MAD - Change in liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)Time frame: Up to 17 weeks
  9. MAD - Change in liver stiffness with Vibration-controlled Transient Elastography (VCTE)Time frame: Up to 17 weeks
  10. MAD - Change in fibrosis markers measured by Enhanced Liver Fibrosis (ELF) scoreTime frame: Up to 17 weeks
  11. MAD - Change in hepatic fat measured by MRI-PDFFTime frame: Up to 17 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • OPKO study site

    Miami, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.